CCR5Δ32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C

World Journal of Gastroenterology

Volumn 12, Issue 29, 2006, Pages 4721-4726

  Goyal, Ankur ^a,b,c   Suneetha, P V ^a   Kumar, G T ^a   Shukla, Deepak K ^d   Arora, Naveen ^b   Sarin, Shiv K ^a,e  

^a G B PANT HOSPITAL   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^e JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

CC chemokine ligand; Histological activity index; Human leukocyte antigen; chemokine receptor 32 bp deletion

Indexed keywords

ALPHA2B INTERFERON; CHEMOKINE RECEPTOR CCR5; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; INFECTION SENSITIVITY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SCORING SYSTEM; TREATMENT OUTCOME; ALLELE; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; DRUG COMBINATION; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; ALANINE TRANSAMINASE; ALLELES; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MUTATION; RECEPTORS, CCR5; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 33747631578     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i29.4721     Document Type: Article

References (34)

1. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga. EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007
2. Dumoulin FL, Bach A, Leifeld L, El-Bakri M, Fischer HP, Sauerbruch T, Spengler U. Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C. J Infect Dis 1997; 175: 681-685
3. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-765
4. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity, Hepatology 1997; 25: 449-458
5. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997; 159: 1012-1018
6. Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, Spengler U. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis 2002; 185: 1803-1807
7. Martin K, Heinzlmann M, Borchers R, Mack M, Loeschke K, Folwaczny C. Delta 32 mutation of the chemokine-receptor 5 gene in inflammatory bowel disease. Clin Immunol 2001; 98: 18-22
8. Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, Volck B, Svejgaard A, Andersen V. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25: 1462-1465
9. Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, Balsa A, Figueroa M, de Juan MD. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999; 42: 989-992
10. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673
11. Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offergeld R, Sauerbruch T, Spengler U. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 2002; 122: 1721-1728
12. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124: 352-360
13. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC, Thursz M, Hill AV. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38: 1468-1476
14. Cha TA, Kolberg J, Irvine B, Stempien M, Beall E, Yano M, Choo QL, Houghton M, Kuo G, Han JH. Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. J Clin Microbiol 1991; 29: 2528-2534
15. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995; 15: 70-81
16. Barber Y, Rubio C, Fernandez E, Rubio M, Fibla J. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users. J Infect Dis 2001; 184: 1279-1288
17. Bosi I, Ancora G, Mantovani W, Miniero R, Verucchi G, Attard L, Venturi V, Papa I, Sandri F, Dallacasa P, Salvioli GP. HLA DR13 and HCV vertical infection. Pediatr Res 2002; 51: 746-749
18. Vejbaesya S, Songsivilai S, Tanwandee T, Rachaibun S, Chantangpol R, Dharakul T. HLA association with hepatitis C virus infection. Hum Immunol 2000; 61: 348-353
19. Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, Airoldi A, Salvaneschi L, Mondelli MU, Ideo G. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28: 1-7
20. Goyal A, Kazim SN, Sakhuja P, Malhotra. V, Arora N, Sarin SK. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol 2004; 72: 60-65
21. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-177
22. Rosen HR, McHutchison JG, Conrad AJ, Lentz JJ, Marousek G, Rose SL, Zamart A, Taylor K, Chou S. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 714-720
23. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-712
24. Husain S, Goila R, Shahi S, Banerjea A. First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 coreceptor-CCR5 gene. Gene 1998; 207: 141-147
25. Nguyen GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, Cohen AR, DiMichele D, Eyster ME, Kessler CM, Konkle B, Leissinger C, Luban N, O'Brien SJ, Goedert JJ, O' Brien TR. Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr 1999; 22: 75-82
26. Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J, Hegarty J, McKiernan S, Kelleher D. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54: 1157-1161
27. Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U. CC-chemokine receptor 5 (CCR5) in hepatitis C - at the crossroads of the antiviral immune response? J Antimicrob Chemother 2004; 53: 895-898
28. Ahlenstiel G, Berg T, Woitas RP, Grunhage F, Iwan A, Hess L, Brackmann HH, Kupfer B, Schernick A, Sauerbruch T, Spengler U. Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. J Hepatol 2003; 39: 245-252
29. Glas J, Torok HP, Simperl C, Konig A, Martin K, Schmidt F, Schaefer M, Schiemann U, Folwaczny C. The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin. Clin Immunol 2003; 108: 46-50
30. Konishi I, Horiike N, Hiasa Y, Michitaka K, Onji M. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology 2004; 47: 114-1120
31. Mascheretti S, Hinrichsen H, Ross S, Buggisch P, Hampe J, Foelsch UR, Schreiber S. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol 2004; 136: 328-333
32. Wald O, Pappo O, Ari ZB, Azzaria E, Wiess ID, Gafnovitch I, Wald H, Spengler U, Galun E, Peled A. The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur J Immunogenet 2004; 31: 249-252
33. Wasmuth HE, Werth A, Mueller T, Berg T, Dietrich CG, Geier A, Schirin-Sokhan R, Gartung C, Lorenzen J, Matern S, Lammert F. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J Mol Med 2004; 82: 64-69
34. Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004; 119: 145-148